Wang C C
Department of Radiation Medicine, Mass. General Hospital Cancer Center, Boston 02114.
Int J Radiat Oncol Biol Phys. 1988 Jun;14(6):1143-6. doi: 10.1016/0360-3016(88)90390-2.
In October 1979 we started an accelerated hyperfractionation program consisting of 1.6 Gy/fraction, 2 fractions/day for 12 days or 38.4 Gy. Due to acute toxicity, the patients were then given a 2-week break and resumed once daily radiation therapy with 1.8 Gy/fraction up to 65 Gy, designated as the b.i.d.-q.d. program. In August 1982, the program was changed and the latter part of the treatment was continued on the twice daily program with 1.6 Gy/fraction for a total of 64 Gy, designated as the b.i.d.-b.i.d. program. We evaluated the local control rates of 140 patients with squamous cell carcinomas arising from the oropharynx, that is faucial tonsil and base of tongue. After these treatment regimens, the 36 month actuarial local rates for the T1-4 lesions were 56% for b.i.d.-q.d. (52 patients) and 85% for b.i.d.-b.i.d. (88 patients) with a p value of 0.0013. For the T1-2 lesions the corresponding rates were 81% (13 patients) and 97% (44 patients) with a p value of 0.53. The difference was marked for the T3-4 lesions, that is 47% vs 77% respectively with a p value of 0.017, and those patients without nodal metastases, that is 46% vs 93% with a p value of 0.00043. The improvement was probably due to marked shortening of the overall treatment course following b.i.d.-b.i.d. accelerated program--in this case 1 1/2 weeks. Our preliminary data suggests that the b.i.d.-b.i.d. program is superior to the b.i.d.-q.d. program. The seemingly improved local control rates for the treatment of oropharyngeal carcinomas requires a clinical prospectively randomized trial for confirmation, that is b.i.d.-b.i.d. versus b.i.d.-q.d. versus standard fractionation (q.d.) program.
1979年10月,我们启动了一项加速超分割方案,每次分割剂量为1.6 Gy,每天2次,持续12天,总计38.4 Gy。由于急性毒性反应,患者随后休息2周,然后恢复每天1次的放射治疗,每次分割剂量为1.8 Gy,直至65 Gy,此方案称为bid-qd方案。1982年8月,方案发生改变,治疗的后半程继续采用每天2次的方案,每次分割剂量为1.6 Gy,总计64 Gy,此方案称为bid-bid方案。我们评估了140例口咽鳞状细胞癌患者的局部控制率,这些癌症发生于口咽,即扁桃体和舌根。经过这些治疗方案后,T1 - 4病变患者在bid-qd方案(52例患者)中的36个月精算局部控制率为56%,在bid-bid方案(88例患者)中为85%,p值为0.0013。对于T1 - 2病变,相应的控制率分别为81%(13例患者)和97%(44例患者),p值为0.53。T3 - 4病变的差异较为显著,分别为47%和77%,p值为0.017;对于无淋巴结转移的患者,差异也较为显著,分别为46%和93%,p值为0.00043。这种改善可能是由于bid-bid加速方案显著缩短了总体治疗疗程——在本研究中为1.5周。我们的初步数据表明,bid-bid方案优于bid-qd方案。口咽癌治疗中看似提高的局部控制率需要通过前瞻性随机临床试验来证实,即比较bid-bid方案、bid-qd方案和标准分割(qd)方案。